Last reviewed · How we verify
Autologous Cellular Therapy with PRP-PC
Autologous Cellular Therapy with PRP-PC involves using a patient's own cells, combined with platelet-rich plasma and platelet concentrate, to stimulate healing and tissue repair.
Autologous Cellular Therapy with PRP-PC involves using a patient's own cells, combined with platelet-rich plasma and platelet concentrate, to stimulate healing and tissue repair. Used for Musculoskeletal injuries and degenerative conditions.
At a glance
| Generic name | Autologous Cellular Therapy with PRP-PC |
|---|---|
| Sponsor | H-CYTE |
| Modality | Biologic |
| Therapeutic area | Regenerative Medicine |
| Phase | Phase 2 |
Mechanism of action
This treatment harnesses the body's natural ability to heal itself by using a patient's own cells, which are then combined with platelet-rich plasma and platelet concentrate to enhance the healing process. The platelet-rich plasma and platelet concentrate contain growth factors that stimulate the growth and proliferation of new tissue, promoting healing and tissue repair.
Approved indications
- Musculoskeletal injuries and degenerative conditions
Common side effects
- Pain
- Swelling
- Bruising
- Infection
- Allergic reactions
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Autologous Cellular Therapy with PRP-PC CI brief — competitive landscape report
- Autologous Cellular Therapy with PRP-PC updates RSS · CI watch RSS
- H-CYTE portfolio CI